Recent News

• 05.08.2025 - Delcath Systems First Quarter 2025 Earnings Call
• 04.24.2025 - Delcath Systems to Host First Quarter 2025 Earnings Call
• 04.09.2025 - Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
• 03.24.2025 - Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
• 03.14.2025 - Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 03.06.2025 - Delcath Systems Fourth Quarter 2024 Earnings Call
• 03.06.2025 - Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
• 02.20.2025 - Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
• 02.14.2025 - Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma

Recent Filings

• 04.01.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.01.2025 - DEF 14A Other definitive proxy statements
• 04.01.2025 - ARS Annual Report to Security Holders
• 03.21.2025 - 8-K Current report
• 03.06.2025 - EX-99.1 EX-99.1
• 03.06.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.06.2025 - 8-K Current report
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.07.2025 - 4 Statement of changes in beneficial ownership of securities